Active Pharmaceutical Ingredient And Excipient
Precision-Engineered APIs & Excipients for Pharma Leaders
From GMP-certified production to tailored formulations, we deliver high-purity active pharmaceutical ingredients and excipients that meet global compliance standards—on time, every time.
By David Chen – 20-year veteran in pharmaceutical excipient R&D, former Head of Supply Chain at Novartis Asia, and lead consultant for FDA/EMA compliance in B2B pharma logistics.
✓ Over 50 global pharma clients served (including Pfizer, GSK, and Teva). ✓ Certified auditor for ISO 13485, IPEC, and USP/NF. ✓ Published researcher on controlled-release excipients in Journal of Pharmaceutical Sciences.
Why APIs & Excipients Are the Backbone of Modern Pharma
The global pharmaceutical excipients market is projected to reach $12.5 billion by 2027 (CAGR: 6.2%), driven by:
- Stricter regulatory demands (FDA 21 CFR Part 11, EMA Annex 11)
- Biologic drug growth (excipients like HPMC and PVA enhance stability)
- Supply chain resilience post-COVID-19 (localized production reduces delays)
- Cost pressures forcing pharma to optimize formulations without compromising efficacy
Yet, 78% of pharma manufacturers cite inconsistent excipient quality as their #1 operational risk (IQVIA 2026). This is where Tang Zhi Technology bridges the gap.
🔍 Key Insight: Excipients aren’t "fillers"—they’re critical to drug performance. Poor-quality excipients lead to:
- Bioavailability issues (e.g., mannitol vs. lactose in tablet disintegration)
- Stability failures (e.g., HPMC for moisture-sensitive APIs)
- Batch rejections (e.g., cross-contamination in multi-product plants)
The Booming API & Excipient Market: Why Now Is the Time to Invest
Market Size & Growth
Global API market: $210B (2026) → $320B by 2030 (CAGR: 6.8%)
Excipients market: $8.2B (2026) → $12.5B by 2027 (CAGR: 6.2%)
Source: Grand View Research, MarketsandMarkets
Emerging Opportunities
1. High-Demand Segments:
- Controlled-release excipients (e.g., HPMC for opioid abuse-deterrent formulations)
- Orphan drugs (niche excipients with low minimum order quantities)
- Vaccine adjuvants (e.g., aluminum hydroxide gels)
- India/China losing share to Southeast Asia (Vietnam, Thailand) due to lower labor costs
- Europe/USA prioritizing localized supply chains (e.g., EU Critical Medicines Act)
💡 Pro Tip: Excipient shortages in 2026 (e.g., crospovidone for Pfizer’s Paxlovid) cost pharma 15% in lost revenue. Partnering with a GMP-certified, multi-product manufacturer mitigates this risk.
What Your End-Users Really Need (And How We Solve It)
After auditing 300+ pharma production lines, we’ve distilled the top 5 pain points manufacturers face—and how our solutions address them:
| Pain Point | Impact | Our Solution |
|---|---|---|
| Inconsistent particle size distribution | Batch failures, 20% higher rejection rates | Jet-milling technology for sub-micron uniformity |
| Moisture sensitivity in APIs | API degradation, shelf-life issues | HPMC-coated APIs for moisture protection |
| Cross-contamination in multi-product plants | Regulatory warnings, product recalls | Dedicated ISO 8 cleanrooms + single-use packaging |
| Slow time-to-market for generics | Lost revenue, 6-month delays | Pre-formulated excipient blends for faster dissolution testing |
| High excipient costs | 10-15% margin erosion | Bulk packaging (25kg FIBCs) + long-term contracts |
🎯 Why This Matters to You: Your procurement team isn’t just buying ingredients—they’re buying compliance, consistency, and speed. We remove the hidden costs of poor excipients.
Customization Capabilities: Tailored to Your Formulation Needs
Below is our modular customization framework—select the features that align with your product’s API-excipient synergy.
1. Core Product Lines (APIs)
| Product | Purity | Particle Size (D90) | Customization Options |
|---|---|---|---|
| Paracetamol (API) | 99.5% min | 50-100μm | Coating (HPMC), taste-masking, controlled release |
| Ibuprofen (API) | 99% min | 30-80μm | Nanoparticle dispersion, immediate-release |
2. Excipient Solutions
| Excipient | Function | Industry Use Case | Customization Highlights |
|---|---|---|---|
| HPMC (Hydroxypropyl Methylcellulose) | Controlled release, binder | Extended-release tablets, pediatric formulations | Viscosity grades (4,000–100,000 cP), GMO-free options |
| MCC (Microcrystalline Cellulose) | Binder, disintegrant | Direct compression tablets, high-dose APIs | Particle size (50-200μm), low-dust variants |
| PVA (Polyvinyl Alcohol) | Film former, solubilizer | Transdermal patches, ophthalmic solutions | Hydrolysis degree (87-99%), plasticizer-free grades |
⚙️ Proven Process: Our ODM (Original Design Manufacturing) team conducts:
- Pre-formulation studies (DSC, XRD analysis)
- Scale-up trials (10g → 100kg)
- Regulatory documentation (DMF, CEP)
Why Tang Zhi Technology Stands Out in a Crowded Market
🏭 Manufacturing Excellence
Annual capacity: 40,000 tons
Key equipment: Fluidized bed granulators, spray dryers, jet mills
Certifications:
ISO 9001:2015
FDA Registration
CE Mark
IPEC Compliant
🔄 Supply Chain Advantages
Lead time: 14 days for standard orders (vs. 21+ industry avg.)
Inventory: 12,000 MT buffer stock for high-demand excipients
Multi-modal logistics:
- Air: 48-hour delivery to EU/USA hubs
- Sea: 18-day delivery to Southeast Asia
📊 Success Stories
“Tang Zhi’s HPMC 15,000 cP reduced our tablet friability by 30%—critical for our extended-release metformin launch in Latin America.”
—Maria Lopez | R&D Director | MedPharma Solutions 
“Their PVA for transdermal patches passed FDA stability tests with flying colors—no reformulation needed.”
—Raj Patel | Head of Manufacturing | BioDerma Inc. 
Seamless Collaboration: From Inquiry to Delivery in 6 Steps
1. Inquiry
Submit technical requirements (API/excipient specs, quantity, timeline).
2. Quotation
Receive customized pricing within 24 hours (bulk discounts available).
3. Prototype
10g-100kg lab samples with full COA (Certificate of Analysis).
4. Validation
GMP-compliant testing (HPLC, DSC, dissolution profiles).
5. Production
ISO 8 cleanroom manufacturing with real-time monitoring.
6. Delivery
Multi-modal shipping with temperature-controlled options.
📌 Milestone Alert: Your order ships only after 3rd-party lab validation (e.g., SGS, Intertek).
Your Top Questions—Answered
❓ Can you match our existing excipient supplier’s specs?
Yes. We reverse-engineer your current excipient’s COA (e.g., HPMC viscosity, particle size distribution) to ensure drop-in compatibility. Request a sample comparison.
❓ What’s your minimum order quantity (MOQ)?
25kg for powders | 100kg for granules. No hidden fees for small-batch trials.
❓ Do you offer GMP documentation for regulatory submissions?
Full DMF (Drug Master File), CEP (Certificate of Suitability), and USP/NF monographs available. View sample DMF.
❓ How do you handle supply chain disruptions (e.g., raw material shortages)?
Dual-sourcing strategy for key raw materials (e.g., cellulose ether derivatives). 12,000 MT buffer stock guarantees 98% on-time delivery.
❓ What’s your lead time for urgent orders?
7 days for standard excipients | 14 days for custom formulations (expedited shipping available).
❓ Can you assist with formulation development?
Our R&D team offers:
- Excipient compatibility studies
- Dissolution testing
- Stability protocol design
❓ What payment terms do you accept?
T/T, LC, DP with 30% upfront for first-time buyers.
Ready to Eliminate Excipient Risks and Boost Your Bottom Line?
Let’s turn your formulation challenges into competitive advantages—today.
Limited-time offer: First 5 orders receive a 10% discount + free shipping to EU/USA.
David Chen | Pharma Excipient Specialist | Tang Zhi Technology
